All data are based on the daily closing price as of February 4, 2025
o
OBI Pharma
4174.TWO
1.79 USD
-0.02
-1.10%
Overview
Last close
1.79 usd
Market cap
470.56M usd
52 week high
2.84 usd
52 week low
1.67 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
265.4778
Price/Book Value
6.3719
Enterprise Value
430.23M usd
EV/Revenue
203.6434
EV/EBITDA
-12.3211
Key financials
Revenue TTM
1.76M usd
Gross Profit TTM
-2.30M usd
EBITDA TTM
-62.67M usd
Earnings per Share
-0.29 usd
Dividend
N/A usd
Total assets
125.90M usd
Net debt
N/A usd
About
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.